此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A First-in-Human Feasibility Study of the Vibrant Stroke Detection Technology During Carotid Endarterectomies

2026年9月24日 更新者:Vibrant Medical Ltd.

The goal of this observational study is to learn whether continuous carotid artery blood flow signals can be recorded reliably during surgery, and whether Vibrant Medical's analysis method can detect measurable changes in those signals, in adults undergoing elective carotid endarterectomy (CEA). During CEA, the surgeon temporarily clamps the internal carotid artery as a routine part of the operation. This produces a brief, controlled and fully reversible stop in blood flow that resembles the blood flow change seen in a large-vessel ischemic stroke.

The main questions it aims to answer are:

  • Can usable, continuous blood flow signals be recorded from both sides of the neck before and during carotid clamping?
  • Do the recorded signals show consistent, repeatable changes that are time-locked to carotid clamping and release across patients?

Participants will have their scheduled surgery as usual. During surgery, two legally marketed, FDA-cleared diagnostic ultrasound systems will record blood flow from the common carotid artery on each side of the neck, before clamping, during clamping and after the clamp is released, for about 20 to 30 minutes in total. The recordings are analyzed later and are not seen or used by the surgical team. No part of the surgery or anesthesia care is changed, and there are no study visits after surgery.

研究概览

详细说明

Background

In-hospital stroke is often recognized late, because patients may be sedated, anesthetized or otherwise unable to report symptoms, and there is currently no cleared device that continuously monitors carotid blood flow to flag a sudden change. Vibrant Medical is developing a wearable, non-invasive ultrasound sensor for this purpose. The element that is first-in-human in this study is Vibrant Medical's analysis method (wave-intensity and bilateral-asymmetry processing of carotid Doppler signals), which has previously been applied only to benchtop flow-phantom and in-vivo ovine data.

Carotid endarterectomy provides a controlled clinical model for this first human evaluation: the internal carotid artery clamp is applied and released by the surgeon as part of standard technique, producing a time-stamped, reversible reduction in carotid flow with no additional risk to the patient.

Study design

This is a prospective, single-center, single-arm, observational feasibility study at Tampa General Hospital / University of South Florida. Signals are acquired with two legally marketed, FDA-cleared Class II diagnostic ultrasound systems, one per side, each used within its cleared Peripheral Vessel indication.

Recording phases

  1. Baseline (pre-clamp): 1 to 2 minutes of continuous recording after stable signal acquisition and before any clamping.
  2. Internal carotid artery clamping: recording from just before clamp application through 1 to 2 minutes of clamping.
  3. Planned non-recording interval: both transducers are removed during arteriotomy, plaque removal and closure.
  4. Reperfusion: transducers are re-applied after closure, if this does not delay the surgical team, and recording continues from before clamp release through 1 to 2 minutes of restored flow.

No surgical step, including clamp timing, is delayed, modified or made contingent on the recordings. If a stable signal is not available when the surgeon is ready, the case proceeds unchanged and the phase is documented as missed.

Data collection and analysis

A study coordinator records time stamps of transducer placement, clamp application and release, and each recording phase on a case report form. Blood pressure, heart rate and the standard-of-care neuromonitoring data for the case are extracted from the anesthesia record and time-stamped to surgical events. Demographic and clinical variables (such as age, sex, BMI, surgical side and ASA class) are abstracted from the medical record. Recordings are exported and analyzed offline by Vibrant Medical research software labeled For Research Use Only; no output is available to the clinical team. Results are summarized descriptively; this feasibility study is not powered for hypothesis testing.

研究类型

观察性的

注册 (估计的)

10

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Avennette Pinto
  • 电话号码:813-505-4787
  • 邮箱:apinto3@usf.edu

学习地点

    • Florida
      • Tampa、Florida、美国、33606
        • Tampa General Hospital
        • 首席研究员:
          • Charles Briggs, MD
        • 副研究员:
          • Jean Bismuth, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Adult patients (18 years or older) scheduled for elective unilateral carotid endarterectomy at Tampa General Hospital, identified by the treating surgical team from the elective operative schedule and approached during a routine pre-surgical encounter.

描述

Inclusion Criteria:

  • Adult patients 18 years of age or older.
  • Scheduled to undergo elective unilateral carotid endarterectomy.
  • Capable of providing written informed consent pre-operatively.
  • No condition precluding placement of an ultrasound transducer at either side of the neck, as determined by the Investigator.

Exclusion Criteria:

  • Emergency or urgent (non-elective) carotid endarterectomy.
  • Planned simultaneous bilateral carotid endarterectomy, which would prevent contralateral recording.
  • Known active neck wound, infection, or skin condition at the intended device application site.
  • Implanted active device at the neck (e.g., vagal nerve stimulator) that could be affected by external ultrasound.
  • Anatomy that prevents transducer contact at either side of the neck, as determined by the Investigator.
  • Enrollment in another interventional clinical study that could confound device performance assessment.
  • Pregnant patients, as determined by standard-of-care pregnancy testing performed prior to surgery.
  • Patients who, in the investigator's judgment, are unable or unlikely to comply with the protocol or to provide valid informed consent.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:CASE_ONLY
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Elective Carotid Endarterectomy Patients

Adults undergoing elective unilateral carotid endarterectomy at Tampa General Hospital. Continuous bilateral common carotid Doppler signals are recorded intra-operatively at pre-clamp baseline, during internal carotid artery clamping, and at reperfusion, for approximately 20 to 30 minutes in total. Surgical and anesthesia care are not modified, and the recordings are not available to the clinical team.

External, non-invasive recording of common carotid artery flow on both sides of the neck using two legally marketed, FDA-cleared Class II diagnostic ultrasound systems, one per side, each used within its cleared Peripheral Vessel indication: Telemed ArtUs EXT-2H with L12-5N40-A4 transducer (510(k) K211248) and Telemed SmartUs EXT-1M with L15-7L40H-5 transducer (510(k) K163121). Recordings are analyzed offline with Vibrant Medical research software (For Research Use Only). No output is shown to the surgical team and no clinical decision is based on the recordings.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percentage of Subjects With Successful Bilateral Carotid Signal Acquisition During Baseline and Internal Carotid Artery Clamping
大体时间:Intra-operative, from pre-clamp baseline through internal carotid artery clamping (single surgical encounter)

A subject is counted as a success when usable, continuous bilateral common carotid flow signal is acquired for the full duration of Phase 1 (pre-clamp baseline) and Phase 2 (internal carotid artery clamping), adjudicated against signal-quality criteria fixed before the first subject is enrolled. Subjects in whom acquisition fails are retained in the denominator. Reported as the percentage of enrolled subjects with an exact (Clopper-Pearson) 95% confidence interval, against a descriptive benchmark of at least 80%. This is not a hypothesis test. Phase 3 (reperfusion) is not part of this measure.

Intra-operative, from pre-clamp baseline through internal carotid artery clamping (single surgical encounter)

次要结果测量

结果测量
措施说明
大体时间
Percentage of Subjects With Successful Bilateral Carotid Signal Acquisition During Reperfusion
大体时间:Intra-operative, from before clamp release through 1 to 2 minutes of reperfusion

Usable, continuous bilateral signal acquired for Phase 3, from before internal carotid artery clamp release through 1 to 2 minutes of restored flow. Reported descriptively and separately from the primary outcome, because both transducers are removed during the endarterectomy and re-application depends on not delaying the surgical team.

Intra-operative, from before clamp release through 1 to 2 minutes of reperfusion
Carotid Flow Signal Characteristics Time-Locked to Internal Carotid Artery Clamp Application and Release
大体时间:Intra-operative, from pre-clamp baseline through reperfusion (single surgical encounter)

Signal characteristics, including flow velocity, wave-intensity and bilateral-asymmetry measures, described per subject relative to the documented clamp application and release time stamps, and summarized descriptively. All enrolled subjects with any recorded data are included; no imputation is performed and missing phases are reported as missing.

Intra-operative, from pre-clamp baseline through reperfusion (single surgical encounter)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Charles Briggs, MD、Tampa General Hospital / University of South Florida

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月1日

初级完成 (估计的)

2027年3月1日

研究完成 (估计的)

2027年3月1日

研究注册日期

首次提交

2026年9月24日

首先提交符合 QC 标准的

2026年9月24日

首次发布 (实际的)

2026年10月1日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月24日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data are coded, held under the data provisions of the clinical trial agreement, and are not planned for sharing. Aggregate study results will be made publicly available through publication or conference presentation.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅